Type 1 diabetes (T1D) is an autoimmune disease in which the immune system destroys the insulin-producing beta cells of the pancreas. Once destroyed, beta cells do not regenerate — making preservation of remaining function in newly diagnosed patients, and immune regulation in established T1D, the primary therapeutic targets for MSC therapy.
Two Mechanisms in T1D
Immune Regulation
The autoimmune attack on beta cells is mediated by autoreactive T-cells targeting pancreatic islet antigens. MSCs suppress this autoreactive T-cell response and expand regulatory T-cells (Tregs), potentially slowing or halting the ongoing autoimmune destruction.
Islet Support
MSCs secrete EGF and HGF — factors that support islet cell survival and reduce beta-cell apoptosis under inflammatory conditions. In animal models of T1D (NOD mice), MSC administration significantly preserves beta-cell mass and delays disease onset.
Clinical Evidence
A 2013 trial in recently diagnosed T1D patients (diagnosed within 6 months) showed that IV MSC therapy significantly increased C-peptide levels at 12 months — indicating preserved beta-cell function — compared to controls. HbA1c improvement and reduced insulin requirements were also observed.
Established T1D (>2 years) with minimal residual beta-cell function shows more limited C-peptide benefit, but immune regulation effects may reduce insulin resistance and improve glycemic variability.
Who Is a Candidate
Newly diagnosed T1D patients (within the first 2 years) with detectable C-peptide have the highest potential for meaningful response. Patients with established T1D are evaluated case-by-case — immune modulation benefits may still be present, but expectations for insulin independence are not appropriate.